ANZCTR search results

This study will evaluate a wellbeing workshop designed for GPs and GP trainees. The workshop is based on research with GPs and will provide them with education about wellbeing and burnout, and include several activities for them to develop a wellbeing plan. Those attending the workshops will be invited to complete a baseline survey, another survey 1 week after the workshop (for feedback on the workshop), and a final survey 3 months after completing the workshop. These surveys will measure GPs' reported burnout levels, sense of value fulfilment, satisfaction with work/life balance, and self-care behaviours.

Insomnia is a prevalent and debilitating disorder in Australia. Cognitive behavioural therapy for insomnia (CBTi) is the recommended 'first line' treatment for insomnia (Qaseem et al., 2016, Ann Intern Med). However, there are very few clinicians in Australia with training in CBTi. Consequently, most patients with insomnia never access CBTi (Miller et al., 2017, JCSM). This project aims to test the effectiveness of a dCBTi intervention in the Australian general practice context. Self-guided and clinician-guided digital CBTi programs are an effective and potentially scalable intervention to manage insomnia. There are very few evidence-based digital CBTi programs available in Australia, and currently no publicly-available digital CBTi programs that provide personalised weekly behavioural therapy recommendations. This cluster randomised controlled implementation trial aims to investigate the effectiveness of three digital treatment options for insomnia in Australian general practice. Following recruitment of eligible patients with insomnia symptoms, general practice clinics will be cluster-randomised 1:1:1 to; 1. Digital sleep hygiene education (treatment as usual control) 2. Self-guided digital cognitive behavioural therapy for insomnia program 3. Clinician-guided digital cognitive behavioural therapy for insomnia program (digital program plus three sessions with general practitioner to provide guidance and motivational support). It is hyopthesised that the groups that receive the digital CBTi program will report a greater reduction in insomnia and depressive symptoms and lower rates of medicine use for insomnia, compared to the group that receive sleep education (control). Furthermore, it is hypothesised that the group that receive clinician-guided digital CBTi will experience greater reduction of insomnia and depressive symptoms, and lower rates of medicine use for insomnia compared to the group that receive self-guided digital CBTi.

Explore the effects of using a mini-bike on levels of physical activity and loads in the body. Our hypothesis is that mini-bikes will elicit low intensity levels of physical activity.

The aim of this project is to evaluate the implementation and effectiveness of delivering the Small Steps for Big Changes diabetes prevention program in the Australian context. The program, developed in Canada, provides training to health coaches (which can be lay persons or peers) to deliver the 6 sessions of 1-on-1 counselling and supervised exercise. The program will be trialled in five sites in South-East Queensland, with a target of 500 clients. It is part of a larger funded evaluation of the program, which is been rolled out across Canada. It is hypothesised that the program will reach a broad range of clients, be effective in changing physical activity and dietary behaviours, be able to be successfully implemented, and be sustainable.

This study aims to compare the impact of Personalised Exercise Rehabilitation for people with Multimorbidity (PERFORM) with traditional cardiac/pulmonary rehabilitation (CPR) on the quality of life of individuals who have both cardiac or pulmonary disease and other additional health conditions. Who is it for? You may be eligible for this study if you are a male or female age 18 or older independently ambulant, with multimorbidity and cardiac or pulmonary disease. Study details Participants will be randomised to receive either PREFORM intervention or pulmonary/cardiac rehabilitation as per guidelines (Alison JA et al. Respirology 2017 and Woodruffe S et al. Heart Lung Circ 2015). The PREFORM intervention involves an 8-week in-person supervised program at a rehabilitation centre, with sessions held twice weekly. Each session will last 2 hours and consist of one hour of exercise training (Move and Improve) and another hour focusing on patient self-care support and education (Health and Wellbeing sessions). After completion of the intervention, participants will be tested for quality of life, exercise capacity, mental health, physical activity, treatment burden, fatigue, pain, breathlessness, adverse events and adherence. It is hoped that findings from this study will help managing these patients effectively with a multidisciplinary approach to address complex disease interactions.

Resection and Plication (RAP) is a new endoscopic procedure that has been shown to improve reflux symptoms. This study aims to compare oesophageal physiology and reflux-related oesophageal acidification as well as symptoms before and after RAP. This work will help to strengthen current understanding of the efficacy of this procedure. Patients must be clinically appropriate and willing to undergo the Resection and Plication endoscopic procedure. Baseline testing (pH studies, manometry and questionnaires) will occur before RAP and 3-6 months post-RAP, to measure change in patient symptoms and physiology.

The purpose of this project is to assess the feasibility, safety and tolerability of synchronous intravesical instillation of gemcitabine and docetaxel for this cohort of patients. Who is it for? Participants are eligible for this study if they are over the age of 18 with confirmed fully resected, high-risk, non-muscle-invasive bladder cancer where BCG treatment has been unsuccessful or cannot be given. Study details Participants will undergo synchronous intravesical administration of gemcitabine and docetaxel. The planned treatment schedule is once a week for six weeks. Participants will then be tested weekly for completion, adverse events, patient-reported outcome, and 3 months recurrence. Translational studies on a small sample of blood collected after the first weekly treatment and on existing bladder tumour specimens will be performed if consent is given. It is hoped that findings from this study will help improve the health outcomes for people with high risk non muscle invasive bladder cancer by providing an alternative treatment option to removal of the bladder when BCG is unsuccessful or cannot be given.

The aim of this study is to find out if transesophageal echocardiography (TOE) is useful for assessing shock in patients with serious injuries, and helping with treatment and resuscitation of shocked patients. The images of the heart taken by the TOE device may help doctors in diagnosing and treating shock, and therefore in resuscitation efforts.

You are invited to participate in a study using TXI, which is a new imaging software in colonoscopy. This has recently been incorporated within the machine used to process pictures of your bowel during colonoscopy and is available for use in our hospital. TXI enhances the colour and texture characteristics of the bowel lining, making subtle changes and abnormalities more noticeable during colonoscopy. This technology can highlight the contrast between a polyp and the surrounding normal tissue, potentially aiding in the detection of small or flat polyps that may otherwise be missed. Our recent experience with this technology suggests it may increase the ability of endoscopists to detect polyps in the bowel and help us make a decision about which ones may need to be removed. Since you are undergoing a colonoscopy to detect or exclude polyps in your bowel, we would like to invite you to participate in this study.

Hypothesis: Infants and young children 4 months to 5 years of age who are commenced on ETI or IVA will have improved and sustained growth and nutritional outcomes, exocrine pancreatic function and sweat chloride levels. Primary aim: To evaluate longitudinal patterns in growth and nutrition in children 4 months to 5 years of age with CF during the first 2 years of treatment with ETI or IVA. Secondary aim: To describe changes in pancreatic function, clinical outcomes and nutritional interventions in children 4 months to 5 years of age with CF during the first 2 years of treatment with ETI or IVA. Longitudinal, ‘real world’ studies are required to better understand the breadth and significance of CF exocrine pancreatic involvement in children with CF who are exposed to early CFTR correction as infants and children and to better understand the nutritional implications.